(i) if so, how this position reflects in price index?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI R. K. JAICHANDRA SINGH): (a) No, Sir.

(b) and (e) and (f) Names of 12 bulk drugs prices of which are reflected in the whole-sale price index are given in the attached Statement alongwith the category under which each bulk drug falls. [*See Question* 1428 supra.]

(c) and (i) Wholesale price index is already under review. While revising the baskat, the production/consumption pattern of all the drugs would be kept in view.

(d) This Ministry monitors the production of 87 bulk drugs in the organised sector. Details of production of bulk drugs are published in the Performance Budget of this Ministry copies of which are available in the Parliament Library.

(g) and (h) Sales turnover of formulations is not monitored. Manufacturers are free to charge their own prices for price decontrolled formulations.

Import of Drugs and Drug Intermediates ates

1491. SHRI RAJNI RANJAN SAHU: Will the Minister of INDUSTRY be pleased to state:

(a) the instances which came to the Government's notice of the imports made of drugs and drug intermediates under the guise of other drugs and drug intermediates along with date and details of each;

(b) whether Government appointed any Committees to investigate the allegations;

(c) if so, what are the details thereof alongwith the names of companies whose establishments were inspected;

(d) whether any of these committees have since investigated and submitted its reports;

(e) if so, when and what were the details of the recommendations of each Committee;

(f) whether any action has been taken by Government on these reports; if so, what are the details thereof;

(g) if the answer to part (f) above be in the negative, what are the reasons therefor; and

(h) by when action will be completed?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI R. K. JAICHANDRA SINGH): (a) to (c) A technical team was constituted by the Government to inquire into allegation of import of D-2 Aminobutanol under the name of DL-2 aminobutanol. The names of companies inspected by the Team are given below:

1. M/s. Lyphin Chemicals.
2. M/s. Dexo Labs.
3. M/s. Themis Chemicals.
4. M/s. Aarati Petrochemicals.
5. M/s. Lupin Labs. Ltd.
6. M/s. Cadila Labs. P. Ltd;

(d) to (f) The Team submitted their report on 5th September, 1984. The Team had come to the conclusion that there was no *prima-facie* evidence to show that D-2 Aminobutanol had been imported in the guise of DL-2 Aminobutanol. The findings of the Team have been accepted by the Government.

(g) and (h) Do not arise.

Information regarding Drug Prices Equalisation Fund Arrears

1492. SHRI RAJNI RANJAN SAHU: Will the Minister of INDUSTRY be pleased to refer to the answer to unstarred Question 619 given in the

Rajya Sabha on the 2nd March, 1987 and state:

(a) whether it is a fact that his Ministry has issued notices to a number of drug companies to provide information in respect of the amount overcharged from the Consumers;

(b) whether it is also a fact that the amounts work out to be more than five hundred crores;

(c) what is the total amount worked out to be collected on account of unintended benefit made on Doxycycline, Centamycin, Tetracycline, Refampicin Ethambutol, Metronidazole, Betamethasone and Dexamethasone since 1980 along with details of each party and amount due; and

(d) how much has been collected and by when the balance amount will be collected?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI R. K. JAICHANDRA SINGH): (a) Yes, Sir.

(b) No, Sir. The final figure of the amount due has not yet been worked out.

(c) The details of unintended benefit on Rifampicin and Sentamycin are given in the attached Statement (See below). In other cases, the amount of unintended benefit made by the companies is yet to be determined.

(d) No further amount has been deposited into the DPEA by any of the companies concerned. Efforts are being made to recover the amount expeditiously.

Statement

(Rs. in l khs)

Sl. No.	Name of the Company	Name of the Bulk Drug	Amount due
1	M/s. Fulford India	Gentamycin	194.62*
2	M/s. Lupin Laboretories	Rifamoicin	215 89
3	M/s. Biochem Pharma Ltd.	Gentamycin	33.88
4	M/s. Biochem Pharma Ltd.	Rifampicin	34 28
5	M/s. Ethico Drugs and Chemicals Mfg. Co.	Rifampicin	141 00
6	M/s. Ranbaxy Laboratories	Rifampicin	26 23
7	M/s. Lyka Laboratories	Gentamycin	27.47

*Includes the amount of Rs. 50 lakhs already deposited by the company into DPEA.

Recovery of Unintended Benefits

1493. SHRI RAJNI RANJAN SAHU: Will the Minister of INDUSTRY be pleased to refer to answer to the Unstarred Question 616 given in the Rajya Sabha on the 2nd March, 1987 and state:

(a) when the amount of unintended benefits was worked out in favour of each company and by when the same will be collected;

(b) whether it is a fact that these amounts are due from 1980;

(c) whether it is also a fact that several hundred crores are due for collection from other parties since last many years;